TY - JOUR
T1 - Burden of breast cancer and attributable risk factors in the North Africa and Middle East region, 1990–2019
T2 - a systematic analysis for the Global Burden of Disease Study 2019
AU - Azadnajafabad, Sina
AU - Moghaddam, Sahar Saeedi
AU - Mohammadi, Esmaeil
AU - Rezaei, Negar
AU - Rashidi, Mohammad Mahdi
AU - Rezaei, Nazila
AU - Mokdad, Ali H.
AU - Naghavi, Mohsen
AU - Murray, Christopher J.L.
AU - Larijani, Bagher
AU - Farzadfar, Farshad
AU - Abbasi-Kangevari, Mohsen
AU - Abbasi-Kangevari, Zeinab
AU - Abbastabar, Hedayat
AU - Abidi, Hassan
AU - Abolhassani, Hassan
AU - Abubaker Ali, Hiwa
AU - Abu-Gharbieh, Eman
AU - Acuna, Juan Manuel
AU - Afrashteh, Sima
AU - Afzal, Muhammad Sohail
AU - Ahmad, Sajjad
AU - Ahmadi, Ali
AU - Ahmadi, Sepideh
AU - Ahmed, Haroon
AU - Ahmed, Luai A.
AU - Rashid, Tarik Ahmed
AU - Ajami, Marjan
AU - Akbarzadeh-Khiavi, Mostafa
AU - Hamad, Hanadi Al
AU - Al-Hanawi, Mohammed Khaled
AU - Ali, Beriwan Abdulqadir
AU - Alimohamadi, Yousef
AU - Alipour, Sadaf
AU - Aljunid, Syed Mohamed
AU - Almustanyir, Sami
AU - Al-Raddadi, Rajaa M.
AU - Alvand, Saba
AU - Arabloo, Jalal
AU - Arab-Zozani, Morteza
AU - Aryannejad, Armin
AU - Ashraf, Tahira
AU - Athari, Seyyed Shamsadin
AU - Jafari, Amirhossein Azari
AU - Bagheri, Nader
AU - Bagherieh, Sara
AU - Bahadory, Saeed
AU - Behnammoghadam, Mohammad
AU - Bhagavathula, Akshaya Srikanth
AU - Bohlouli, Somayeh
N1 - Publisher Copyright:
Copyright © 2023 Azadnajafabad, Saeedi Moghaddam, Mohammadi, Rezaei, Rashidi, Rezaei, Mokdad, Naghavi, Murray, Larijani, Farzadfar and GBD 2019 NAME Breast Cancer Collaborators.
PY - 2023
Y1 - 2023
N2 - Background: Breast cancer (BC) is the most common cancer in women globally. The North Africa and Middle East (NAME) region is coping hard with the burden of BC. We aimed to present the latest epidemiology of BC and its risk factors in this region. Methods: We retrieved the data on BC burden and risk factors from the Global Burden of Disease Study 2019 to describe BC status in the 21 countries of the NAME region from 1990 to 2019. We explored BC incidence, prevalence, deaths, disability-adjusted life years (DALYs), and attributable burden to seven risk factors of female BC, namely, alcohol use, diet high in red meat, low physical activity, smoking, secondhand smoke, high body mass index, and high fasting plasma glucose. Decomposition analysis on BC incidence trend was done to find out the contributing factors to this cancer’s growth. Results: In 2019, there were 835,576 (95% uncertainty interval: 741,968 to 944,851) female and 10,938 (9,030 to 13,256) male prevalent cases of BC in the NAME region. This number leads to 35,405 (30,676 to 40,571) deaths among female patients and 809 (654 to 1,002) deaths in male patients this year. BC was responsible for 1,222,835 (1,053,073 to 1,411,009) DALYs among female patients in 2019, with a greater proportion (94.9%) of burden in years of life lost (YLLs). The major contributor to female BC incidence increase in the past three decades was found to be increase in age-specific incidence rates of BC (227.5%), compared to population growth (73.8%) and aging (81.8%). The behavioral risk factors were responsible for majority of attributable female BC burden (DALYs: 106,026 [66,614 to 144,247]). High fasting plasma glucose was found to be the risk factor with the largest effect (DALYs: 84,912 [17,377 to 192,838]) on female BC burden. Conclusion: The increasing incidence and burden of BC in the NAME region is remarkable, especially when considering limited resources in the developing countries of this region. Proper policies like expanding screening programs and careful resource management are needed to effectively manage BC burden.
AB - Background: Breast cancer (BC) is the most common cancer in women globally. The North Africa and Middle East (NAME) region is coping hard with the burden of BC. We aimed to present the latest epidemiology of BC and its risk factors in this region. Methods: We retrieved the data on BC burden and risk factors from the Global Burden of Disease Study 2019 to describe BC status in the 21 countries of the NAME region from 1990 to 2019. We explored BC incidence, prevalence, deaths, disability-adjusted life years (DALYs), and attributable burden to seven risk factors of female BC, namely, alcohol use, diet high in red meat, low physical activity, smoking, secondhand smoke, high body mass index, and high fasting plasma glucose. Decomposition analysis on BC incidence trend was done to find out the contributing factors to this cancer’s growth. Results: In 2019, there were 835,576 (95% uncertainty interval: 741,968 to 944,851) female and 10,938 (9,030 to 13,256) male prevalent cases of BC in the NAME region. This number leads to 35,405 (30,676 to 40,571) deaths among female patients and 809 (654 to 1,002) deaths in male patients this year. BC was responsible for 1,222,835 (1,053,073 to 1,411,009) DALYs among female patients in 2019, with a greater proportion (94.9%) of burden in years of life lost (YLLs). The major contributor to female BC incidence increase in the past three decades was found to be increase in age-specific incidence rates of BC (227.5%), compared to population growth (73.8%) and aging (81.8%). The behavioral risk factors were responsible for majority of attributable female BC burden (DALYs: 106,026 [66,614 to 144,247]). High fasting plasma glucose was found to be the risk factor with the largest effect (DALYs: 84,912 [17,377 to 192,838]) on female BC burden. Conclusion: The increasing incidence and burden of BC in the NAME region is remarkable, especially when considering limited resources in the developing countries of this region. Proper policies like expanding screening programs and careful resource management are needed to effectively manage BC burden.
KW - breast cancer
KW - epidemiology
KW - Global Burden of Disease
KW - Middle East
KW - North Africa
KW - risk factor
UR - http://www.scopus.com/inward/record.url?scp=85168275996&partnerID=8YFLogxK
U2 - 10.3389/fonc.2023.1132816
DO - 10.3389/fonc.2023.1132816
M3 - Article
AN - SCOPUS:85168275996
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1132816
ER -